NRCT 202XR
Alternative Names: NRCT-202-XRLatest Information Update: 09 Dec 2024
Price :
$50 *
At a glance
- Originator Neurocentria
- Class Behavioural disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Attention-deficit hyperactivity disorder
Most Recent Events
- 21 Nov 2024 Phase-II clinical trials in Attention-deficit hyperactivity disorder (In adolescents, Combination therapy) in USA (unspecified route) (NCT06673368)
- 21 Nov 2024 Phase-II clinical trials in Attention-deficit hyperactivity disorder (Monotherapy, In adolescents) in USA (unspecified route) (NCT06673368)
- 12 Nov 2024 Preclinical trials in Attention-deficit hyperactivity disorder in USA (unspecified route) prior to November 2024 (NCT06673368)